A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

A recent study from the University of Hong Kong suggests that a newer type of diabetes drug, called sodium-glucose cotransporter 2 inhibitors (SGLT2i), may help protect the kidneys and lungs in people ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...